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Background and Aims: aneurysmal bone cysts represent about 1% of primary bone 
tumors. The standard treatment is curettage, followed by local adjuvant treatments and 
bone grafting. The problem is the high recurrence rate. The purpose of this study was to 
evaluate retrospectively the use of bioactive glass as a filling material in the treatment of 
aneurysmatic bone cysts in children.
Material and Methods: a total of 18 consecutive children (mean 11.3 years at surgery; 
10 males; 11 lower, 6 upper limb, 1 pelvis; 15 with primary surgery) with histologically 
proven primary aneurysmal bone cysts operated with curettage and bioactive glass filling 
between 2008 and 2013 were evaluated after a mean follow-up of 2.0 years (range, 0.7–
5.1 years).
Results: Two (11%) patients showed evidence of aneurysmal bone cyst recurrence and 
both have been re-operated for recurrence. Bone remodeling was noted in all patients 
with remaining growth and no growth plate disturbances were recorded. Two patients 
needed allogeneic blood transfusion. no intraoperative or postoperative complications 
were recorded.
Conclusion: We conclude that bioactive glass is a suitable filling material for children 
with primary aneurysmal bone cyst. Bioactive glass did not affect bone growth and no 
side effects were reported.
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INTRODUCTION
Primary aneurysmal bone cyst (ABC) is a rare lesion 
with an incidence of 1.4 per 105 individuals and repre-
sents about 1% of primary bone tumors (1). The stand-
ard treatment is to remove the lesion by curettage, 
followed by local adjuvant treatment and bone graft-
ing. The rate of local recurrence has varied widely (2). 
Recurrences are more likely in younger children, with 
open growth plates and within the first 2 years postop-
eratively (3).
A number of adjunctive therapies are used to 
decrease the rate of recurrence. The local recurrence 
can be kept to a minimum if curettage is thorough and 
is performed with a high-speed burr (3). Phenol is a 
nonselective cytotoxic agent, which destroys the 
remaining residual tumor and normal cells (4) and has 
been used in the treatment of ABCs (5).
Bioactive glasses (BG) are bone bonding, osteocon-
ductive bone substitutes with bone-stimulative and 
antibacterial and angiogenesis-promoting properties 
(6). Bioactive glass BG-S53P4 gained European 
approval as a bone graft substitute in 2006. BG-S53P4 
has been reported to be safe and well-tolerated and 
suitable for benign bone tumor surgery with good 
long-term results in adults (6). In one case report of a 
4-year-old girl with phalangeal ABC, BG-S53P4 did 
not disturb the growth of bone (7). BGs dissolve slowly 
and the graft area remodels to bone over time. This 
phenomenon may be beneficial, especially in the treat-
ment of ABCs, which are prone to recur (7).
The aim of this study was to evaluate BG as a filling 
material in children’s ABCs. We also aimed to describe 
the effect of BG on further growth and bone remodeling.
MATERIAlS AND METHODS
After Institutional Review Board and Ethics commit-
tee approval, the patients with aneurysmatic bone cyst 
were identified from three University Central Hospital 
databases. The medical records and radiographs of 
children presenting with a bone lesion treated with 
bioactive glass between 2008 and 2013 (40 cases) were 
reviewed retrospectively. Other than ABC lesions 
were excluded. We found 18 patients with histologi-
cally proven primary ABCs treated with curettage and 
bioactive glass filling.
Variables reviewed were date of birth, gender, age 
at presentation, pre- and postoperative imaging stud-
ies, the affected bone, cyst location versus physis, size 
of cyst, possible pathologic fracture, type and date of 
surgical procedure, the use of possible preoperative 
embolization or injection treatment, possible intraop-
erative adjuvant treatments, histology, recurrence, and 
other possible complications during treatment.
Preoperative and postoperative radiographs were 
available for all patients. In all, 17 of 18 patients had 
magnetic resonance imaging (MRI) of the lesion preop-
eratively; the remaining patient had computer tomog-
raphy (CT) imaging. Three patients had both CT and 
MRI before treatment. Postoperatively, two patients 
had CT during follow-up and one patient had MRI and 
one both MRI and CT during follow-up to evaluate 
possible recurring cyst suspicion on plain radiographs. 
One of these patients was symptomatic (pain). The 
 volumes of the lesions on MR and CT images were 
measured using Aycan Workstation OsiriXpro (version 
1.04; Wurzburg, Germany) (8). CT and MR images as 
well as radiographs were analyzed by radiologist with 
special experience and interest in musculoskeletal 
radiology. Cysts were classified according to Capanna’s 
and Enneking’s classification systems (9,10).
Four patients underwent biopsy before surgical 
treatment. In all, 11 patients had frozen section during 
surgery before filling the cavity with bioactive glass. 
In all patients, the final histologic examination con-
firmed the presence of an ABC.
The operation included curettage of the lesion with 
high-speed burr and filling the cavity with bioactive 
glass, BG-S53P4 (BonAlive Biomaterials ltd). Phenol 
was used as a cytotoxic agent in 12 patients.
ETHICS
The study has Institutional Review Board (5 September 
2012) and Ethics committee approval (19 June 2012).
RESUlTS
The mean age at the time of surgery was 11.3 years 
(range, 4–16 years). There were 10 male patients (mean 
age of 10.8 years; range, 4–16 years) and 8 female 
patients (mean age, 11.9; range, 7–15 years). The mean 
follow-up was 2.0 years (range, 0.7–5.1 years) from the 
date of initial surgery. Eight ABCs were type 1 (44%) in 
Capanna’s classification system, six were type 2 (33%), 
and four (22%) were type 3 cysts. Two of the cysts 
(11%) were inactive in Enneking’s classification sys-
tem, 12 (66%) were active, and four (22%) were aggres-
sive lesions (Tables 1 and 2).
The locations of the cysts are shown in Table 1. The 
most commonly involved bone was femur (six cases). 
One patient had massive aneurysmatic bone cyst of 
the pelvis (Fig. 1A to C). The lower limbs were involved 
more frequently (11 cases) than upper limbs (6 cases). 
Eight patients had a pathologic fracture before opera-
tion. Seven of these fractures had healed before sur-
gery using conservative treatment. None of the 
patients underwent preoperative embolization. One 
patient had had sclerotherapy twice before operation.
Three patients had been operated previously for the 
cyst. In two patients, the index operation was a second 
and in one a third. In all three patients, allogeneic bone 
grafting had been used in previous operations.
Plate fixation was used in eight patients. Phenol 
was used in 12 patients. Bone autograft was appli-
cated in addition to bioactive glass in one patient with 
cuneiforme mediale and another with third metatarsal 
ABC. Two patients were given allogeneic red blood 
cell transfusion postoperatively. No perioperative 
complications were recorded.
In the study period, two patients developed a recur-
rent lesion (Tables 1 and 2):
1. Patient No. 1 was 16 years at the time of the opera-
tion. The index operation was the third for the 
aneurysmatic bone cyst in the proximal femur. 
Phenol was used as adjunctive therapy. The pre-
senting symptom was pain. A recurrence was 
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 suspected on plain radiographs and confirmed 
with MR and CT imaging.
2. Patient No. 17 was a 4-year-old boy who had revi-
sion surgery after filling with allograft. MR images 
confirmed the recurrence. When allograft was 
used, the curettage was not total because the cyst 
grew to the distal femur physis.
Both patients had active lesions according to 
Enneking’s classification system. Patient No. 1 had 
type 1 lesion in Capanna’s classification system and 
patient No. 17 had type 3 lesion.
There were no side effects to BG reported in 
patient’s files. All 14 patients with open growth plates 
continued to grow normally without any disturbances. 
Additionally, these patients showed bone remodeling 
with increased density on radiographs in the operation 
area. In all patients, some ill-defined glass granules were 
still visible among new bone at the end of follow-up.
DISCUSSION
ABC’s origin is controversial. Over the past few years, 
many different genetic translocations have been 
described in ABC, all resulting in oncogenic activation 
of the USP6 gene. USP6 is an ubiquitin-specific pro-
tease that was identified as an oncogene in transfec-
tion experiments with Ewing sarcoma DNA. Recently, 
structurally similar USP6 fusion genes were identified 
in both ABC and nodular fasciitis. This suggests that 
these conditions are clonal neoplastic disorders that 
may belong to the same biologic spectrum (11).
Because of ABC’s controversial origin, no universal 
treatment method has been adopted. Opinion varies 
as to which method should be used, especially in chil-
dren. Only few pediatric studies exist, the biggest ones 
being the study of Dormans et al. (5) and Ramirez and 
Stanton (12). To the best of the authors’ knowledge, 
there is only one case report using BG to treat a recur-
rent ABC in a child (7).
En-bloc resection is not a common procedure and 
must be considered only when there is no other alter-
native (2). Intralesional excision with bone grafting is 
usually the standard cure. However, curettage with or 
without bone grafting has been associated with high 
recurrence rates (2, 13, 14).
A number of adjunctive therapies are used to decrease 
the rate of recurrence (5, 15, 16). Varshney et al. (17) ana-
lyzed the literature regarding the treatment of ABCs, 
founding recurrence rate of approximately 29.2% when 
curettage and bone grafting are used. This decreased to 
15.4% using high-speed burr (3, 5, 17).
Sclerotherapy is a newer treatment method. An 
alcoholic solution of zein (Ethibloc) has been used 
with good healing rates (18). Polidocanol has been 
used as a sclerosant with 3% recurrence rate (19). It is 
TABlE 2
Patients with aneurysmatic cyst and complications.






Complications during follow-up Residive size 
(cm3)
1 – 5.1 I Residive/residual, 1 year 2 months after operation, new 
operation (BG + phenol + pediatric hip plate)
II Residive 3 years 4 months after operation, aethoxysklerol
1.920 (I)
1.899 (II)
2 – 6 2.4 –  
3 – 5 3.0 –  
4 – 1 1.4 –  
5 – 3 1.6 –  
6 – 1 1.4 –  
7 – 2 4.7 –  
8 – 6 1.0 –  
9 – 2 1.6 –  
10 – 1 0.7 –  
11 – 2 2.0 –  
12 Bleeding 6 2.0 –  
13 – 1 1.2 Block from crista, bioactive glass around it, stress fracture 
7 months after operation
 
14 – 3 2.9 –  
15 – 1 1.4 Block from crista, bioactive glass around it. During follow-
up arthrosis between cuneiforme bones and tarsometatarsal 
I and II. Medial cuneiforme sclerotic and deform. Patient 
asymptomatic
 
16 Bleeding, possible 
not enough 
curettage
8 0.8 Possible residual 4 months postoperatively in X-ray. later area 
fulfilled
 
17 – 2 1.2 In first operation, cyst was filled with allograft, 8 months 
postoperatively residive, filled with bioactive glass, II residive/
residual in MRI 8 months postoperatively
6.5385/0.4474
18 – 2 1.4 Sclerotherapy twice before bioactive glass filling. Minimal 
residual after operation, not expansive in follow-up
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reported that repetitive sclerotherapy is safer method 
than intralesional excision and bone grafting with 
similar recurrence rates (17). However, there are also 
problems with this treatment method. Complications 
(pulmonary embolism, aseptic fistulae, infection, 
osteomyelitis, and abscess) have been reported in the 
literature (18, 20). Fatal brain stem and cerebellar 
infarction have also been described (21). Repetitive 
injections are usually needed and general anesthesia is 
required for children (17, 22). Brosjö et al. (22) found 
no growth disturbances in their series. When there is 
large ABC in weight-bearing bone, it is impossible to 
stabilize the bone to reduce the risk of pathologic frac-
ture when using sclerotherapy as a sole treatment 
method. Therefore, the current authors would not use 
sclerotherapy as a sole treatment in high risk locations 
for pathological fractures such as proximal femoral 
area. In our study, internal fixation was commonly 
used for large cysts, especially in lower extremities, to 
prevent early pathologic fractures and to allow early 
weight bearing and motion.
Selective arterial embolization of the nutrient ves-
sels is an alternative method in difficult locations such 
as spine and pelvis. Ischemia to neural and vital struc-
tures remains the main concern (15). In spine repeated 
embolization, when feasible, can be considered the 
first treatment option (23, 24), but this leads into high 
radiation doses.
Recurrence rates after curettage vary widely from 
9% (5) to 71% (25). In a literature review, the recur-
rence rate of the 690 ABCs treated with curettage 
with or without bone graft was 31% (2). In our small 
series of 18 patients treated with bioactive glass, 
two patients developed recurrence (11%). Both were 
male and had active and large lesions nearby growth 
plates of the proximal and distal femur, respectively, 
and previously surgically treated using allograft 
bone. Additionally, phenol as an adjuvant had not 
been used in the first patient. Because of the retro-
spective nature of this study, there was no routine 
schema for radiographic controls. The potential 
recurrences were evaluated from plain radiographs. 
When recurrence was suspected, MR imaging was 
done (also CT in one patient). Only four patients 
had MR or CT imaging postoperatively. Patients 
with recurrent cysts had active cyst in Enneking’s 
classification and type 1 and 3 lesions in Capanna’s 
classification.
In our series, there were no growth arrests when 
evaluating the growth plate on radiographs. Other 
Fig. 1. A) Preoperative radiograph from the patient who had massive aneurysmatic bone cyst of the pelvis. B) Immediate radiograph after 
curettage and bioactive glass filling. C) Three years from the curettage and bioactive glass filling.
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studies have reported growth problems (4%/12.5%/ 
14.3%) (15, 17, 26). Physeal growth arrest appears to be 
related more to the location of the cyst and surgical 
technique than the filling material itself and the role of 
filling material in this respect is not clearly known. 
Juxtaphyseal ABC involvement has been reported to 
have growth disturbance in 55% following surgical 
treatment (27, 28). Appositional growth seems not to be 
affected by filling using bioactive glass (7). All patients 
in our study showed bone remodeling with dense, 
more sclerotic appearance in the operation area. 
However, limitation is that we made remodeling obser-
vations only on radiographs which may lead to an 
impression of a more sclerotic area than it actually is (6).
Bioactive glass proved to be a safe filling material of 
bone cavity after curettage of primary ABC. Its resist-
ance to mechanical compression might be beneficial in 
cases of recurrent ABC. These properties may limit the 
expansion of the lesion as all our recurrences were 
small. In previous studies, the size of the recurrence 
has not been studied. Bioactive glass also allowed 
bone remodeling in all patients with remaining growth 
and did not disturb further growth even in small chil-
dren. In conclusion, bioactive glass is a suitable filling 
material for children with primary ABC. Bioactive 
glass did not affect bone growth and no side effects 
were reported. The recurrence rate of primary ABC 
after operation appears acceptable.
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